January 15th 2025
Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.
Combination Effective Treating Non Small Cell Lung Cancer
June 4th 2018Pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate in 41% in patients with advanced non–small cell lung cancer, according to findings presented at the 2018 ASCO Annual meeting.
Creating an Aligned Care Plan in HIV, Oncology
May 29th 2018Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses HIV and oncology distinction programs and how these standards bring patients, physicians, and pharmacists together to align care.